News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
505–540
Matches
929
Sources here
12
Companies here
20
Search results Stored financial headlines

Active search

929 matching headlines

Ticker or company: IMMMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Immutep Ltd Sponsored ADR Revenue Breakdown – FWB:YP1A

The article provides a financial overview and market data for Immutep Ltd Sponsored ADR (FWB:YP1A) on the Frankfurt Stock Exchange. It highlights the company's financial statements, statistics, dividends, earnings, and segments, indicating a focus on its fundamental performance. No specific revenue breakdown figures are …

IMMP main company
Sharemaestro market context Price below Trend Line 52 weeks -78.5% IMMP stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Simmons First National Corporation $SFNC Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp reduced its stake in Simmons First National Corporation (SFNC) by 3.9% in the first quarter, selling over 62,000 shares but still holding 1.54 million shares worth approximately $29.9 million. Institutional investors collectively own 27.58% of SFNC, and analysts …

SFNC main company
Sharemaestro market context Trend signal active 52 weeks +20.4% SFNC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

IMMX|Immix Biopharma Inc|Price:8.690|Chg%:+0.170

This article provides detailed market trends and financial analysis for Immix Biopharma Inc (IMMX), including real-time quotes, key figures, and analyst ratings. It highlights that seven analysts currently rate IMMX as "Buy" with a target price of $20.714, representing a 143.13% upside. The company …

IMMX main company
Sharemaestro market context Trend signal active 52 weeks +400.9% IMMX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Lyell Immunopharma Market Sentiment

This article provides an overview of Lyell Immunopharma's (LYEL) market sentiment, detailing key signals such as analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with a high average price target, while options flow indicates a bearish sentiment with …

LYEL main company
Sharemaestro market context Price below Trend Line 52 weeks +29.6% LYEL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Immuron Ltd (IMRN) Cash Flow

This article provides an in-depth look at Immuron Ltd (IMRN) cash flow statements, including operating, investing, and financing cash flows, both quarterly and annually. It highlights the company's negative operating cash flow and free cash flow in the latest fiscal period, alongside explanations of …

IMRN main company
Sharemaestro market context Trend signal active 52 weeks -38.2% · Next-week setup negative 39.5% IMRN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Lyell Immunopharma, Inc. (LYEL) holder pays broker with 44,000 shares

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc. (LYEL), transferred 44,000 shares of common stock to Wuxiong, Inc. This transfer served as a non-cash broker commission related to a development milestone under a license agreement dated November 6, 2025. Following …

LYEL main company
Sharemaestro market context Price below Trend Line 52 weeks +29.6% LYEL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Immunic Inc (IMUX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Immunic Inc (IMUX), noting its current valuation score of 9.22, which ranks 48 out of 386 in its industry. The company's P/E ratio is reported as -0.95, significantly differing from its recent high and low. Data for …

IMUX main company
Sharemaestro market context Trend signal active 52 weeks +69.1% IMUX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Bitmine (BMNR) Jumps 13% on More ETH Buy, Ahead of Clarity Act Vote

Bitmine Immersion climbed by 13.49 percent on Monday to finish at $17.92 apiece, after reinforcing its position as one of the market's emerging crypto treasury firms with the recent acquisition of nearly 10,000 Ethereum tokens, while investors positioned ahead of next week's expected passage …

BMNR main company BMNR main company
Sharemaestro market context Price below Trend Line 49 weeks -66.8% BMNR stored weekly price path from 12 Sep 2025 to 14 Aug 2026

Immatics N.V. (NASDAQ:IMTX) Given Consensus Rating of "Moderate Buy" by Analysts

Eight analysts covering Immatics N.V. (NASDAQ:IMTX) have issued a "Moderate Buy" consensus rating, with six recommending a buy, one a hold, and one a sell. The average 12-month price target is $20.80, significantly above the current $9.08 share price, and institutional investors own 64.41% …

IMTX main company
Sharemaestro market context Price below Trend Line 52 weeks +65.9% IMTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Troluce Capital Advisors LLC Acquires Shares of 250,000 Immatics N.V. $IMTX

Troluce Capital Advisors LLC recently acquired 250,000 shares of Immatics N.V. (NASDAQ:IMTX) for approximately $2.46 million, establishing a new position in the company. Despite Immatics missing Q1 analyst estimates for revenue and EPS, and receiving mixed analyst ratings with some recent downgrades, the consensus …

IMTX main company
Sharemaestro market context Price below Trend Line 52 weeks +65.9% IMTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Altimmune Inc Financials

This article provides a detailed financial summary of Altimmune Inc (ALT), including its latest stock price, market capitalization, and key financial indicators. It presents extensive quarterly and annual data for EPS, Revenue, Net Profit, Balance Sheet items, and Cash Flow, based on reports up …

ALT main company
Sharemaestro market context Price below Trend Line 52 weeks -16.9% ALT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Altimmune Inc (ALT) Balance Sheet

This article provides detailed balance sheet data for Altimmune Inc (ALT), allowing users to evaluate its financial health through quarterly and annual figures. It includes key financial metrics like cash and short-term investments, total assets, liabilities, and shareholders' equity, along with supporting FAQs. The …

ALT main company
Sharemaestro market context Price below Trend Line 52 weeks -16.9% ALT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Broker commission transfer of 38,500 shares in Lyell Immunopharma (LYEL)

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma (LYEL), transferred 38,500 shares of common stock to LifeSci Advisors, LLC as broker commission on July 27, 2026. This transfer was related to the first Development Milestone payment under a November 6, 2025 …

LYEL main company
Sharemaestro market context Price below Trend Line 52 weeks +29.6% LYEL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

IMTX|Immatics NV|Price:8.800|

This article from TradingKey provides a comprehensive stock analysis of Immatics NV (IMTX), highlighting its strong fundamentals, significant growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes high institutional ownership and multiple "Buy" ratings from analysts, despite a …

IMTX main company
Sharemaestro market context Price below Trend Line 52 weeks +65.9% IMTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Immersion Corp earnings beat by $0.21, revenue topped estimates

Immersion Corp (NASDAQ: IMMR) reported strong Q2 earnings, beating analyst estimates with an EPS of $0.300 against a predicted $0.093. The company also surpassed revenue expectations, bringing in $270M compared to the consensus of $230M. Immersion Corp's stock has shown positive performance over the …

IMMR main company
Sharemaestro market context Trend signal active 52 weeks +9.4% · Next-week setup negative 43.2% IMMR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for AC Immune SA (ACIU), covering business segments and regional contributions. However, it explicitly states that the relevant data for these categories has not been disclosed by the company. Therefore, the content primarily highlights …

ACIU main company
Sharemaestro market context Price below Trend Line 52 weeks +15.8% ACIU stored weekly price path from 22 Aug 2025 to 14 Aug 2026

ICCC|ImmuCell Corp|Price:11.135|Chg%:+0.105

This article provides a comprehensive stock analysis of ImmuCell Corp (ICCC) from TradingKey, highlighting its healthy fundamentals, high growth potential, and a 'fairly valued' assessment within the Pharmaceuticals industry. The analysis notes strong institutional ownership and anticipates an upward trend in the medium term, …

ICCC main company
Sharemaestro market context Trend signal active 52 weeks +64.9% ICCC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Bitmine Added ETH While Strategy's BTC Lull Continues

Two of crypto's biggest corporate treasuries moved in opposite directions last week, as Strategy sat out Bitcoin buying for the 5th week in a row while Bitmine added another chunk of ETH to its stack. What's the Scoop? Strategy's buildup: Its 843,775 BTC holding …

BMNR main company BMNR main company
Sharemaestro market context Price below Trend Line 49 weeks -66.8% BMNR stored weekly price path from 12 Sep 2025 to 14 Aug 2026

Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Estrella Immunopharma Inc (ESLA). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page displays basic stock information such as market …

ESLA main company
Sharemaestro market context Price below Trend Line 52 weeks -25.4% · Next-week setup negative 43.1% ESLA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Monday's ETF Movers: IGV, PSI

In trading on Monday, the iShares Expanded Tech-Software Sector ETF is outperforming other ETFs, up about 3.9% on the day. Components of that ETF showing particular strength include shares of Asana, up about 14.2% and shares of Bitmine Immersion Technologies, up about 13% on …

BMNR main company BMNR main company
Sharemaestro market context Price below Trend Line 49 weeks -66.8% BMNR stored weekly price path from 12 Sep 2025 to 14 Aug 2026

Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Immunovant Inc (IMVT)'s dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents other financial data …

IMVT main company
Sharemaestro market context Trend signal active 52 weeks +174.4% · Next-week setup negative 44.7% IMVT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BMNR Stock Climbs As Massive Ethereum Bet Draws Trader Focus

BMNR stock climbed by 12.7% due to strong positive sentiment surrounding BitMine Immersion Technologies Inc.'s massive Ethereum holdings. The company holds approximately 4.8% of the total ETH supply, aiming for 5%, and has staked 4.9M ETH for projected annual staking revenues of $242–$290M. Despite …

BMNR main company
Sharemaestro market context Price below Trend Line 52 weeks -66.2% · Next-week setup positive 55.5% BMNR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak

Immunocore Holdings is strategically shifting its focus beyond its single rare-cancer drug, Kimmtrak, leveraging its T-cell receptor platform into broader markets. This expansion includes testing its technology in various solid tumor indications, infectious diseases, and autoimmune conditions. While Kimmtrak remains a commercial success, the …

IMCR main company
Sharemaestro market context Trend signal started 52 weeks +3.9% IMCR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead

Immunocore's primary product, Kimmtrak, generated $400 million in sales in 2025, demonstrating strong growth potential, especially with new five-year survival data supporting its first-line positioning for metastatic uveal melanoma. The company has significant catalysts ahead in 2026, including potential expansion into larger cutaneous melanoma …

IMCR main company
Sharemaestro market context Trend signal started 52 weeks +3.9% IMCR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?

Immunocore Holdings (IMCR) presents a mixed investment profile despite strong Kimmtrak sales growth, with revenues up 14% year-over-year but missing analyst estimates. The company maintains a robust cash position of $844.9 million, funding a pipeline of late-stage and early-stage programs. However, its valuation trades …

IMCR main company
Sharemaestro market context Trend signal started 52 weeks +3.9% IMCR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Bitmine Nears Goal of Controlling 5% of Ethereum Supply With $11.8 Billion Treasury

Crypto treasury firm BitMine Immersion Technologies said Sunday it has increased its Ethereum holdings to 5.79 million ETH, bringing its combined crypto holdings, cash, marketable securities, and strategic investments to $11.8 billion as it moves closer to its goal of acquiring 5% of Ethereum's …

BMNR main company BMNR main company
Sharemaestro market context Price below Trend Line 49 weeks -66.8% BMNR stored weekly price path from 12 Sep 2025 to 14 Aug 2026

ImmuCell Corp (ICCC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of ImmuCell Corp's (ICCC) dividend history, noting that the company has not distributed any dividends over the past five years. It presents current stock price information and links to more detailed financial and corporate data. The page indicates that …

ICCC main company
Sharemaestro market context Trend signal active 52 weeks +64.9% ICCC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Shimmick Corp (SHIM) Cash Flow

This article provides the quarterly and annual cash flow statements for Shimmick Corp (SHIM), detailing its operating, investing, and financing cash flows. It includes a tabular presentation of financial data for various quarters and years, alongside frequently asked questions that define different types of …

SHIM main company
Sharemaestro market context Price below Trend Line 52 weeks +22.6% SHIM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Immersion Corp (IMMR) Reports Q4 Results; GF Score™ at 58 Reflects Mixed Financial Health

Immersion Corporation (IMMR) reported a decline in Q4 revenue to $270.0 million from $284.9 million year-over-year, alongside a GAAP EPS of $0.30. The company's GF Score™ of 58/100 indicates moderate financial health, with strong profitability (8/10) but concerns in financial strength (5/10) and valuation …

IMMR main company
Sharemaestro market context Trend signal active 52 weeks +9.4% · Next-week setup negative 43.2% IMMR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Strategy Climbs 3%, BitMine Surges 7%, SharpLink Rises 5% as Crypto Stocks Bounce Back Toward $65K Bitcoin

Quick Read A U.S. Iran strike pause triggered a relief rally, lifting MSTR 6% and BMNR 13%, but both stocks remain negative over the past year. SharpLink's institutional ownership surged from 6% to 46%, and its $125 million Galaxy Digital (GLXY) on-chain yield fund …

BMNR main company BMNR main company
Sharemaestro market context Price below Trend Line 49 weeks -66.8% BMNR stored weekly price path from 12 Sep 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context